Who are novel treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, Open-label, PK Cohort (Cohort B): ponsegromab low dose, oseltamivir and chinese medicinal herbs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/novel-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

novel treatment — Competitive Intelligence Brief

novel treatment (novel treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule. Area: Oncology.

marketed Small molecule Unknown Oncology Small molecule Live · refreshed every 30 min

Target snapshot

novel treatment (novel treatment) — Imperial College London. This novel treatment works by targeting a specific molecular pathway to produce a therapeutic effect.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
novel treatment TARGET	novel treatment	Imperial College London	marketed	Small molecule	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
Open-label, PK Cohort (Cohort B): ponsegromab low dose	open-label-pk-cohort-cohort-b-ponsegromab-low-dose	Pfizer	marketed	Unknown	Unknown
oseltamivir and chinese medicinal herbs	oseltamivir and chinese medicinal herbs	Capital Medical University	marketed	Neuraminidase inhibitor combined with herbal supplement	Influenza viral neuraminidase; herbal targets unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Small molecule class)

Pfizer · 3 drugs in this class
Akorn, Inc. · 1 drug in this class
Guangdong Hengrui Pharmaceutical Co., Ltd · 1 drug in this class
Health Research, Inc. · 1 drug in this class
Imperial College London · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 drug in this class
Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
UroGen Pharma Ltd. · 1 drug in this class
Abivax S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). novel treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/novel-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab